Keywords: Lundbeck, Merck & Co, Sycrest, Saphris, Genmab, CNS antibody, Antipsychotic

Denmark’s Lundbeck buys rights to Merck & Co’s antipsychotic Sycrest; enters deal with Genmab

Article | 13 October 2010

Print This

Danish drugmaker Lundbeck A/S (LUND: DC) announced a worldwide commercialization agreement with US drugs giant Merck & Co (NYSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in